Medicsight Appoints Aburrow-Jones as Manager
06.07.2005 / 08:48 / Rubriek: Informatief / Organisatie: Medicsight
Medicsight Appoints Aburrow-Jones as Product and Accounts Manager
LONDON, July 6/PRNewswire/ --
Medicsight Inc.'s (OTC Bulletin Board: MSHT) majority owned subsidiary, Medicsight PLC ('Medicsight'), announced today the appointment of Jonah Aburrow-Jones to the newly created position of product and accounts manager. Aburrow-Jones will be responsible for managing client relationships with Medicsight's worldwide partners. In addition, he will also handle product management activities for Medicsight's Colon CAR(TM), Lung CAR(TM) and future products.
Aburrow-Jones joins Medicsight with more than 12 years of product management and sales experience, most recently serving as the senior product line manager for the Voxar Product Group of Barco. Prior to Barco, he was product manager - International for E-Z-EM, Inc., an international manufacturer of contrast agents for gastrointestinal radiology. He has extensive industry and clinical experience and has successfully developed and managed sales, marketing and product development teams.
'We're pleased to welcome Jonah to our growing team,' said Tim Paterson-Brown, Medicsight CEO. 'Jonah's medical imaging experience will be very valuable as Medicsight continues to cultivate its partner base and as we drive the development of new products, expanding our product range into new clinical areas.'
The position of product and accounts manager became effective June 2005 and will be based in Medicsight's headquarters in London.
About Medicsight
Medicsight is a software development business focused on the medical imaging market. The company is using its core technology to develop automatic detection and analytical tools for clinicians to improve their ability to diagnose and treat disease, initially focusing on three key clinical areas -- lung cancer, colon cancer, and coronary heart disease. Medicsight's software will enable earlier and more accurate detection and treatment of suspicious lesions, which can save lives and reduce healthcare costs. Headquartered in London, Medicsight employs more than 60 people and has offices in the U.K., United States, Japan and China. Product and company information can be found on www.medicsight.com . Stock symbol: OTCBB:MSHT
All forward-looking statements are made pursuant to the 'safe harbor' provisions of the Private Securities litigation Reform Act of 1995. Forward-looking statements are based on current management expectations that involve risks and uncertainties that may result in such expectations not being realized. Potential risks and uncertainties include, but are not limited to, the risks described in company filings with the Securities and Exchange Commission.
Web site: www.medicsight.com
Source: Medicsight
Lindsay Vidrine of Fleishman-Hillard, 314-982-1723, or David Sumner, Medicsight International Marketing Director, +44 (0)20 7598 4080, or David Mason, Medicsight Investor Relations, +1-615-665-9007